Last reviewed · How we verify
ALXN1850
ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.
ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases. Used for C3 glomerulopathy, Post-infectious glomerulonephritis.
At a glance
| Generic name | ALXN1850 |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Complement C3 inhibitor |
| Target | Complement C3 |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Immunology |
| Phase | Phase 3 |
Mechanism of action
ALXN1850 selectively inhibits complement C3 activation within the proximal tubule of the kidney, preventing downstream complement cascade amplification and tissue damage. This targeted approach aims to preserve kidney function while minimizing systemic complement inhibition, reducing the risk of infections associated with broader complement blockade.
Approved indications
- C3 glomerulopathy
- Post-infectious glomerulonephritis
Common side effects
- Infection
- Gastrointestinal disorders
- Headache
Key clinical trials
- Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (PHASE3)
- Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (PHASE3)
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (PHASE3)
- Study of ALXN1850 in Participants With Hypophosphatasia (HPP) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |